Clovis Oncology Inc. (CLVS) Has Soared To A New High On Phase 3 Study Results


Shutterstock photo

(RTTNews.com) - Clovis Oncology Inc. ( CLVS ) announced Monday morning that its Phase 3 trial of rucaparib successfully achieved the primary endpoint of improved progression-free survival in patients with ovarian cancer.

Clovis Oncology has gapped open dramatically higher this morning and is now up 27.53 at $87.50 on above average volume. The stock has soared to a new high for the year.

For comments and feedback: contact editorial@rttnews.com




This article appears in: Stocks , Politics
Referenced Symbols: CLVS


More from RTT News

Subscribe






See headlines for CLVS

Follow on:








Research Brokers before you trade

Want to trade FX?